Acer Therapeutics is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat illnesses, including multiple sclerosis as well as other autoimmune diseases such as neuromyelitis optica (NMO). Co. has been developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO. NMO is an autoimmune disorder in which immune system cells and antibodies attack astrocytes causing to the secondary destruction of nerve cells (axons) in the optic nerves and the spinal cord. OPX-212 is specifically tailored to each patient's immune response to a protein, aquaporin-4 expressed by astrocytes, which is the targeted antigen in NMO.

OPXA — News

OPXA — Price Chart